Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

FDA approves suzetrigine, a non-opioid painkiller that blocks sodium channels, offering potent relief without addiction risks.

In 2004, a research group at Peking University First Hospital discovered a mutation in the gene coding for a sodium-channel ...

The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in November, ...

The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for adults experiencing moderate to severe acute pain. Journavx received FDA ...

Journavx (suzetrigine) is said to reduce pin by "targeting a pain-signaling pathway involving sodium channels in the ...

Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.

Vertex Pharmaceuticals’ suzetrigine, which will be marketed under the name Journavx, targets specific sodium channels that ...

Nerve cells are the information carriers in our brain. When transferring signals, they change their electrical charge by ...